Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8520437 | 1.00 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL7976110 | 1.00 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL7990244 | 1.00 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL8520440 | 1.00 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL7976120 | 1.00 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL7976124 | 1.00 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL7987971 | 0.90 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL7987975 | 0.90 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL7987976 | 0.90 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL7976595 | 0.87 | LTB4R (1.00) | LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6291530-B1 | Aryl-substituted acrylamides with Leukotriene B4 (LTB-4) receptor antagonist activity | NOVARTIS AG (CH) | 2001-09-18 | — | — | US | claimed |
| US-6291530-B1 | Aryl-substituted acrylamides with Leukotriene B4 (LTB-4) receptor antagonist activity | NOVARTIS AG (CH) | 2001-09-18 | — | — | US | disclosed |
| EP-0942903-A1 | ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY | Novartis AG (CH) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998013347-A1 | ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 1998-04-02 | — | — | WO | disclosed |